Producing MSC-derived cell therapies: workflows, technologies, and case studies
Year: 2025
Type: article
Abstract: In this expert roundtable, four highly experienced industry professionals discuss key considerations in mesenchymal stem (or stromal) cell (MSC) manufacturing, including reagent selection, dosing, delivery methods, and final product formulation. The panelists also explore emerging modalities such as induced pluripotent stem cell (iPSC)-derived MSCs, gene-engineered MSCs, and exosome-based therapies, and emphasize the need for cost reduction and scalable manufacturing to improve accessibility and clinical success.
Source: Cell and Gene Therapy Insights
Authors: Irana Malaspina, Shirley Mei, Tony Ting, Whitney Wilson
Institution: Ottawa Hospital Research Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4417330241
FWCI:
Cites:
Cited by:
Related to: